The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Trial-in-progress: tazemetostat with rituximab for R/R follicular lymphoma
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, gives an overview of a Phase II trial-in-progress (NCT04762160) exploring tazemetostat, a first-in-class, oral, selective enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with rituximab for patients with relapsed/refractory (R/R) follicular lymphoma who have previously received two lines of systemic therapy including an anti-CD20-based regimen. The primary endpoint of this trial is overall response rate (ORR) in patients with wild-type EZH2. Secondary endpoints include progression-free survival, ORR in patients with mutated EZH2, and efficacy outcomes in patients who are refractory to rituximab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
